Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms 124-Iodine labeled monoclonal antibody G250, 124-Iodine labeled WX-G250, Girentuximab I-124 + [7] |
Target |
Mechanism CAIX inhibitors(Carbonic anhydrase IX inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Neoplasms | Phase 3 | US | 01 Mar 2008 | |
Renal Cell Carcinoma | Phase 3 | US | 01 Mar 2008 | |
Transitional Cell Carcinoma | Phase 2 | AU | 30 Jan 2022 | |
Transitional Cell Carcinoma | Phase 2 | DE | 30 Jan 2022 | |
Triple Negative Breast Cancer | Phase 1 | AU | 30 Jan 2022 | |
Triple Negative Breast Cancer | Phase 1 | DE | 30 Jan 2022 |
Phase 1 | 26 | 124-Iodine-cG250 (124I-cG250) | utovywuxgr(rzmbswyvkv) = onyjrtziiq oogxpfvutp (tediykexbd, odpwapflfn - kblwbnhkpa) View more | - | 14 May 2021 |